The Role of the Amylin Analogue Cagrilintide in Bone Metabolism
NN9388-8175
Phase 1 other active
Quick answer
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism for Female (aged between 50-70 years (both included)) with obesity (BMI ≥ 30.0 kg/m2) of post-menopausal state at screening (defined as minimum 12 months of amenorrhea and high levels of follicular stimulating hormone (FSH) ≥16 UI/L. In cases of uncertainty, confirmation of postmenopausal status requires low levels of anti-Müllerian hormone (AMH) and inhibin B). is a Phase 1 program (other) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novo Nordisk A/S
- Indication
- Female (aged between 50-70 years (both included)) with obesity (BMI ≥ 30.0 kg/m2) of post-menopausal state at screening (defined as minimum 12 months of amenorrhea and high levels of follicular stimulating hormone (FSH) ≥16 UI/L. In cases of uncertainty, confirmation of postmenopausal status requires low levels of anti-Müllerian hormone (AMH) and inhibin B).
- Phase
- Phase 1
- Modality
- other
- Status
- active